RXST Announces CEO Transition Following Preliminary 2Q Results; Maintain Neutral

Research evidence excerpt

RXST Announces CEO Transition Following Preliminary 2Q Results; Maintain Neutral

July 15, 2026 RxSight, Inc.

(RXST, Neutral)MEDICAL Ryan Zimmerman

RXST Announces CEO Transition Following Preliminary 2Q Results; (212) 527-3586 rzimmerman@btig.com

Maintain Neutral Iseult McMahon

(332) 400-5103 imcmahon@btig.com

WHAT YOU SHOULD KNOW: Post close on July 15th, RXST announced the appointment Company Data

of Aziz Mottiwala as CEO as of July 20th, 2026. Current CEO, Ron Kurtz, will transition Closing Price $5.25

into the role of Chief Medical Officer. This announcement comes roughly one week

Price Target - after RXST announced a collaboration agreement with Alcon (ALC, Buy, $82 PT)

Market Cap (M) $216.86TECHNOLOGY (here), preliminary 2Q26 results, and updated FY26 guidance. We are not entirely

surprised by the leadership transition given where RXST stands commercially and Enterprise Value (M) $(9.20)

efforts need to improve commercial traction. The partnership with ALC represents Shares Out (M) 41.31

a meaningful step forward in the broader development of the LAL technology and Avg Daily Vol-3 Months (M) 1.04

bringing in a commercially experienced operator like Mr. Mottiwala makes sense whileEQUITY Revisions also retaining Dr. Kurtz as CMO. The ALC collaboration is a meaningful development

but will take time. RXST continues to face headwinds from macro pressures on Previous Current

elective procedure volumes, competitive dynamics in the IOL market, and declining LAL Rating Neutral Neutral

utilization, and we see limited line of sight to a sustained recovery in the underlying Price Target - -

business presently. At current valuation levels, we view shares as fairly valued until FY26E REV 129.08 129.08

there is greater evidence of a commercial inflection. Maintain Neutral.